Icthic Magazine

Home › Archive

Anticoagulant and antiplatelet treatment in cancer patients with thrombocytopenia and preliminary data from the MATTER study: A talk report from the 10th ICTHIC conference

During the 10th ICTHIC, Dr. Avi Leader (hematologist at Rabin Medical Center in Petah Tikva, Israel) talked about...

Blood clot generation in people with cancer follows a process distinct from the non-cancer population. Cancer tissue is...

D-dimer is a marker of coagulation activation and thrombotic activity. The analysis of D-dimer levels is used to...

Patients with cancer are at high risk of venous thromboembolism (VTE). Fortunately, patient survival, diagnostic tools...

During the 10th ICTHIC, Prof. Marcello di Nisio (University of Chieti, Italy) and Prof. Marc Carrier (Ottawa Hospital...

Atrial fibrillation (AF) is common in patients with cancer, and up to one in every four persons with AF has comorbid...

The management of cancer-associated venous thrombosis (CAT) is particularly challenging because of a high risk of major...

Patients with cancer and a Khorana score ≥2 have an estimated risk of symptomatic venous thromboembolism (VTE) of...

Patients with cancer represent a major challenge for venous thromboembolism (VTE) treatment because of their higher...

José Antonio Páramo is a Professor of Hematology at the University Clinic of Navarra, University of Navarra,...